Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2026.584 | A Phase IIIb, multi-center, two-arm, randomized, doubleblind, parallel group study to evaluate the efficacy and safety of zigakibart and atrasentan versus zigakibart and placebo in patients with primary IgA nephropathy (LUMINA IgAN) | Prof. Szeto Cheuk Chun |
| 2026.586 | A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia | Dr. LOONG Herbert Ho Fung |
| 2026.595 | A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF VVD-133214 IN COMBINATION WITH PEMBROLIZUMAB COMPARED TO PEMBROLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH ADVANCED COLORECTAL ADENOCARCINOMA (CRC) HARBORING MICROSATELLITE INSTABILITY (MSI) AND/OR DEFICIENT MISMATCH REPAIR (DMMR) | Dr. Chan Landon Long |
| 2026.596 | ULTRA-UC: Head-to-Head Evaluation of Intestinal Ultrasound Scoring Systems for Predicting Histologic Remission and Clinical Outcomes in Ulcerative Colitis | Dr. Lau Ivan Shun Fai |
| 9406(S) | A Prospective Randomized Phase III Study Comparing the Combination of Cisplatin, Doxorubicin, Interferon-Alpha-2B and 5-Fluorouracil to Doxorubicin Alone in the Treatment of Inoperable Hepatocellular Carcinoma | Prof. YEO Winnie |
Page 288 of 288.